|
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers
STATEMENT OF NEED
Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)
This 30-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine.
This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
Pathways to Developing Personalized Treatment Regimens for Patients with Advanced Melanoma
No two patients with advanced melanoma are the same and tailoring treatment is vital. Immerse yourself in this interactive “choose your path” digital algorithm with expert perspectives to assist with the application of new guidelines and treatment options to optimize therapy.
Do you have questions about treating patients with advanced melanoma? Do you wonder…
• When to use immune checkpoint inhibitors (ICIs), and in which combinations?
• How to select among the growing number o... |
|
|
Office Practice of Primary Care Medicine 2024 - LIVE STREAMING
The Comprehensive 2024 Update on Office-Based Primary Care Medicine
Taught Live Online by Harvard Medical School's Leading Clinical Faculty
Office Practice of Primary Care Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.
OVERVIEW
Office Practice of Primary Care Medicine provides comprehensive reviews of the most important recent advances impacting primary care medicine and guidance to assimilate these changes... |
|
|
Skin Cancer Education for Primary Care
This comprehensive course on skin cancer will help you improve your ability to diagnose and manage skin lesions, the most common of all cancers.
Outcome Objectives:
As a result of completing this activity, the participant will be better able to:
- Understand the biology of ultraviolet radiation and methods to protect the skin.
- Demonstrate increased proficiency in the management of potentially malignant skin lesions.
- Make early diagnoses of skin cancers, particularly melanoma.... |
|
|
Pulmonary and Critical Care Medicine 2024 - LIVE STREAMING
Comprehensive Updates for State-of-the-Art Evaluation, Diagnosis, and Treatment
This comprehensive live streaming online course, which is among the highest-rated Harvard Medical School CME courses, provides education and updates to optimize your care of patients with:
• Sepsis
• ARDS
• Sarcoidosis
• IPF
• Bronchiectasis
• Cystic fibrosis
• Lung nodules
• Lung cancer
• GERD
• Pleural disease
• Pneumonia
• Tuberculosis
• Thromboembolism
• Chronic cou... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|
|
The Role of the Clinical Pharmacist in the Management of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ... |
|
|
Anesthesiology Update 2024 - LIVE STREAMING or IN PERSON
The Comprehensive 2024 Anesthesiology Update
Cardiac, Regional, Office-Based, Thoracic, Obstetric, Neuro, and Pediatric
Anesthesiology Update will be held on May 6-10, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA.
In the past year, there have been a number of very significant clinical changes that affect the practice of anesthesiology. This comprehensive CME program provides a special and timely opportunity for anesthesiolo... |
|
|
Combining Locoregional and Systemic Therapy for Challenging HCC Cases
Target Audience
This educational activity is intended for interventional oncologyists physicians, nurses, and other members of the health care team who care for patients with hepatocellular carcinoma (HCC)
Program Overview
This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings.
Learning Objectives
Upon c... |
|
|
Optimizing Transition from Pediatric to Adult Care - LIVE STREAMING
In this special program, faculty from Harvard Medical School, the Brigham Transition Care Team, and the Boston Children’s Hospital BRIDGES Adult Transition Program provide strategies, best practices, and guidance to:
• Identify adult care providers and successfully transfer patients with rare or complex health care needs
• Assess and improve the efficacy of your current transition processes
• Tailor transition strategies to patient age, disease type, and physical/ intellectual capab... |
|
|
Innovations and New Practices in Internal Medicine 2024 -LIVE STREAMING
The State of the Art in Internal Medicine
This program, which is among the highest-rated Harvard Medical School CME courses, provides a comprehensive update of the most important changes now impacting Internal Medicine and guidance on how to incorporate these changes into your clinical practice to improve patient outcomes..
Practical, Fast-Paced, Online Education
This live streaming educational experience is fast paced, relevant to the current healthcare environment, and draws upon real... |
|
|
Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and invest... |
|
|
Disparities in Ovarian Cancer: Increasing Awareness to Improve Risk Assessment and Outcomes
Ovarian cancer is the most common cause of cancer death in women with gynecologic malignancy and the fifth leading cause of cancer death in the US. Although the incidence of ovarian cancer is higher among White women than Black women, studies have identified disparities in assessment, care and outcomes seen among Black women with ovarian cancer. It has been shown that outcomes in clinical oncology can be improved when care is delivered by high performance teams. This activity was designed by ... |
|
|
How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r... |
|
|
Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ... |
|
|
Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a... |
|
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
|
Gastroenterology 2024 - LIVE STREAMING
The Comprehensive 2024 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2024 program include:
• Updated... |
|
|
Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
... |
|
|
TOP 10 Early Cancer Detection Queries What You Need to Know About Blood-Based Screening in Primary Care
In this “Top 10 Early Cancer Detection Queries” program, Dr. Mylynda Massart answers the 10 questions most commonly asked by primary care clinicians about blood-based multi-cancer early detection (MCED) tests. Some of the topics addressed are the science behind MCEDs, their accuracy, how MCEDs compare to other screening modalities, and integration of MCED testing into primary care practice. |
|
|
Top 10 COVID-19 Special Population Queries
Even though the COVID-19 pandemic is slowly becoming endemic, there are still certain populations at higher risk of progressing to severe COVID-19 should they become infected with SARS-CoV-2. These include immunocompromised groups, older patients, patients with HIV, disabilities, challenges in social determinants of health, and racial or ethnic minorities. There are treatment considerations for many of these populations, including drug-drug interactions. In this self-directed activity, Drs. Gl... |
|
|
Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings
Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25% of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-base... |
|
|
Intensive Review of Nephrology - LIVE STREAMING
With over 70 interactive lectures, case discussions, board preparation sessions, and supplementary lectures, this CME program provides a comprehensive review of state-of-the-art nephrology practices offered by the clinical faculty of Harvard Medical School.
It offers accelerated learning for:
- Clinicians seeking a practical and comprehensive review that ensures they are up to date across all major areas of nephrology:
• The latest options for diagnosis: what to choose, when, and wh... |
|
|
Hitting The Bullseye in NSCLC
Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation ... |
|
|
Clinical Competence in Breast Imaging, Interventions and Management
Clinical Competence in Breast Imaging, Interventions and Management provides a complete tutorial in all modalities, diagnostic strategies and interventional considerations encountered in the modern breast imaging practice. Its fifty cases allow the participant to explore a wide range of benign and malignant disease, with special focus placed on the variety of presentations and patterns of enhancement observed on mammogram, ultrasound, MRI and tomosynthesis. This activity also expounds on the... |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
Nursing and Nutrition: Providing Survival Skills
Nursing and Nutrition: Providing Survival Skills is designed to help nurses provide basic nutritional guidelines for hospitalized patients. Upon completing this course, they will be able to guide patients to a healthy lifestyle that will aid in their recovery. The course includes food do's and dont's as related to specific issues, such as heart failure, cancer treatment, wound care, etc. |
|
|
LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity
Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho... |
|
|
Nursing Management of Tumor Lysis Syndrome
STATEMENT OF NEED
Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current advances in cancer therapies can increase the incidence of TLS; therefore, identification of patien... |
|
|
Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage
Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management. |
|
|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|
|
Answering The Call in Nonadvanced Systemic Mastocytosis
Target Audience
The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).
Program Overview
Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. In this unique and engaging Call-a-Colleague program, a panel of... |
|
|
Can You Compete in Early Cancer Detection
This activity is an informative and engaging presentation about blood-based multi-cancer early detection MCED screening in the primary care setting. Drs. Massart, Vega, and Whittington will provide key data related to current gaps in cancer surveillance, the science and data behind MCEDs, and information on how to implement MCED screening into practice. |
|
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
|
Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams
An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity mana... |
|
|
Tropical Charms of the Seychelles: Hot Topics in Medical, Dental & Public Health Issues
Discover paradise as you sail the Indian Ocean for 7 nights on a luxury Seychelles yacht cruise with PES! Nestled over 900 miles from mainland Africa in the topaz waters of the Indian Ocean, lies the blissful Seychelles Islands. Brimming with incredible landscapes, rare wildlife, and a vibrant atmosphere, a Seychelles cruise will introduce you to East Africa’s archipelago of utopia, all while enjoying the all-inclusive, 100-guest Emerald Azzurra.
Hot Topics in Medical, Dental & Public... |
|
|
Nurses Light the Path: Empowering Patients to Improve Breast Cancer Screening and Clinical Trial Representation
Target Audience
The primary target audience for this activity is Oncology Nursing Professionals (APRN, NP, RN).
Program Overview
For women with breast cancer and those at risk, disparities in screening and clinical-trial enrollment exist, particularly among racial and ethnic minority populations. Awareness of these disparities can ensure timely screening practices and help address patient fears and concerns regarding clinical trials that inhibit diverse representation in research. Younger... |
|
|
Recent Advances in the Treatment and Management of Endometrial Cancer
This live activity is designed for oncologists, obstetrics & gynecologists, primary care physicians, nurses and pharmacists engaged in the care of patients with endometrial cancer. This activity will represent a thorough team approach to patient care.
Further, this activity will address the following needs:
Clinicians require a review of risk factors and symptoms of endometrial cancer, as well as appropriate management of patients.
Clinicians need further education regarding new and... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|